Clinical trials
Sarcoma trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Unknown status | 6 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 7 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 6 |
| Eisai Inc. | 3 |
| Eli Lilly and Company | 3 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2 |
| Hoffmann-La Roche | 2 |
| Pfizer | 2 |
| Philogen S.p.A. | 2 |
| Alaunos Therapeutics | 1 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sarcoma | 39 |
| Leiomyosarcoma | 7 |
| Liposarcoma | 7 |
| Histiocytoma, Malignant Fibrous | 6 |
| Sarcoma, Synovial | 6 |
| Fibrosarcoma | 5 |
| Rhabdomyosarcoma | 5 |
| Neoplasm Metastasis | 4 |
| Neoplasms | 4 |
| Neurofibrosarcoma | 4 |
Trials
Showing 51 to 39 of 39. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.